![](/img/cover-not-exists.png)
Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
Taro Goto, Shinji Fujikoshi, Kazunori Uenaka, Shinichi Nishiuma, Eric R. Siemers, Robert A. Dean, Michihiro TakahashiVolume:
6
Year:
2010
Language:
english
DOI:
10.1016/j.jalz.2010.05.1003
File:
PDF, 45 KB
english, 2010